Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + pegaspargase
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intramuscular
01
Overview
The combination of sintilimab and pegaspargase is an investigational regimen for the treatment of advanced or early-stage extranodal natural killer/T-cell lymphoma (ENKTL/NKTCL). Sintilimab is a fully human anti-PD-1 monoclonal antibody that blocks the PD-1/PD-L1 immune checkpoint, thereby enhancing T cell-mediated antitumor immunity. Pegaspargase is an anti-metabolic agent, a modified form of L-asparaginase, which depletes asparagine in tumor cells, leading to selective cytotoxicity in lymphoblasts and certain lymphoma cells. This chemo-free regimen has demonstrated promising efficacy and safety in clinical trials for newly diagnosed advanced stage NKTCL[6][9].
- Other names
- sintilimab plus pegaspargasepegaspargase plus sintilimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sintilimab + pegaspargase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + pegaspargase.